Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2005-01-25
2005-01-25
Ketter, James (Department: 1636)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C435S366000, C435S440000, C435S455000, C435S456000, C435S459000, C435S461000, C435S463000
Reexamination Certificate
active
06846676
ABSTRACT:
The invention provides primary and secondary cells that are transfected with a nucleic acid molecule that encodes erythropoietin, clonal or heterogenous strains of such cells, and methods of producing these cell strains.
REFERENCES:
patent: 4396601 (1983-08-01), Salser et al.
patent: 4497796 (1985-02-01), Salser et al.
patent: 4789550 (1988-12-01), Hommel et al.
patent: 4892538 (1990-01-01), Aebischer et al.
patent: 4980286 (1990-12-01), Morgan et al.
patent: 5082670 (1992-01-01), Gage et al.
patent: 5089397 (1992-02-01), Kushner et al.
patent: 5166059 (1992-11-01), Pastan et al.
patent: 5175255 (1992-12-01), Thomason et al.
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5219740 (1993-06-01), Miller et al.
patent: 5272071 (1993-12-01), Chappel
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5441868 (1995-08-01), Lin
patent: 5460959 (1995-10-01), Mulligan et al.
patent: 5464764 (1995-11-01), Capecchi et al.
patent: 5578461 (1996-11-01), Sherwin et al.
patent: 5789215 (1998-08-01), Berns et al.
patent: 5994127 (1999-11-01), Selden et al.
patent: 6048524 (2000-04-01), Selden et al.
patent: 6048729 (2000-04-01), Selden et al.
patent: 6054288 (2000-04-01), Selden et al.
patent: 6063630 (2000-05-01), Treco et al.
patent: 0038765 (1981-03-01), None
patent: 0236059 (1987-09-01), None
patent: 0255231 (1988-02-01), None
patent: 0289034 (1988-11-01), None
patent: 0452894 (1991-10-01), None
patent: 2159172 (1985-11-01), None
patent: WO 8700201 (1987-01-01), None
patent: WO 8905345 (1987-12-01), None
patent: WO 8800239 (1988-01-01), None
patent: WO 8907136 (1988-02-01), None
patent: WO 8808306 (1988-03-01), None
patent: WO 9006997 (1988-12-01), None
patent: WO 8901517 (1989-02-01), None
patent: WO 9012878 (1989-05-01), None
patent: WO 9015863 (1989-06-01), None
patent: WO 9006757 (1990-06-01), None
patent: WO 9011354 (1990-10-01), None
patent: WO 9207573 (1990-10-01), None
patent: WO 9212242 (1990-12-01), None
patent: WO 9215676 (1991-03-01), None
patent: WO 9106666 (1991-05-01), None
patent: WO 9106667 (1991-05-01), None
patent: WO 9109955 (1991-07-01), None
patent: WO 9113151 (1991-09-01), None
patent: WO 9119796 (1991-12-01), None
patent: WO 9203917 (1992-03-01), None
patent: WO 9208796 (1992-03-01), None
patent: WO 9219255 (1992-11-01), None
patent: WO 9220808 (1992-11-01), None
patent: WO 9304169 (1993-03-01), None
Osborne et al. (1988) Design of vectors for efficient expression of human purine nucleoside phosphorylase in skin fibroblasts from enzyme-deficient humans. Proc. Natl. Acad. Sci. USA 85:6851-6855, Sep. 1988.*
Palmer et al. (1989) Production of human factor IX in animals by genetically modified skin fibroblasts: potential therapy for hemophila B. Blood 73:438-445, Feb. 1989.*
Browne et al. (1986) Erythropoietin: Gene cloning, protein structure, and biological properties. Cold Spring Harbor Symposia Quant. Biol. 51:693-702, 1986.*
EP Opposition Apr. 30, 1998, On behalf of Genetic Therapy, Inc.
EP Opposition Apr. 30, 1998, On behalf of Institut Pasteur.
EP Opposition May 4, 1998, On behalf of Boehringer Mannheim GMBH.
EP Opposition May 4, 1998, On behalf of Applied Research Systems.
EP Opposition May 4, 1998, On behalf of Cell Genesys, Inc.
Antin et al., “Single Cell Analysis of Transfected Gene Expression in Primary Heart Cultures Containing Multiple Cell Types,” BioTechniques 6:640-648, 1988.
Barr et al., “Systemic Delivery of Recombinant Proteins by Genetically Modified Myoblasts,” Science, 254:1507-1509, 1991.
Behr et al., “Efficient Gene Transfer Into Mammalian Primary Endocrine Cells with Lipopolyamine-coated DNA,” Proceedings of the National Academy of Sciences U.S.A. 86:6982-6986, 1989.
Bennett et al., “A Role for Cyclosporin A in Gene Replacement Therapy,” American Journal of Human Genetics 45:A109, 1989.
Bennett et al., “Suppression of Immunological Response Against a Novel Gene Product Delivered by Implants of Genetically Modified Fibroblasts,” Molecular Biology and Medicine, 7:471-477, 1990.
Boggs, “Targeted Gene Modification for Gene Therapy of Stem Cells,” International Journal of Cell Cloning 8:80-96, 1990.
Brash et al., “Strontium Phosphate Transfection of Human Cells in Primary Culture: Stable Expression of the Simian Virus 40 Large T-Antigen Gene in Primary Human Bronchial Epithelial Cells,” Molecular and Cellular Biology 7(5):2031-2034, 1987.
Brenner et al., “Expression of Collagen Genes in the Liver,” Molecular Biology and Medicine 7:105-115, 1990.
Brigham et al., “Expression of Prokaryotic Gene in Cultured Lung Endothelial Cells after Lipofection with a Plasmid Vector,” Am. Journal of Respiratory Cell. and Molecular Biology 1:95-100, 1989.
Browne et al., “Erythropoietin: Gene Cloning, Protein Structure, and Biological Properties,” Cold Spring Harbor Symposia on Quantitative Biology, vol. LI, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, p. 693-702, 1986.
Burrin et al., “Regulation of Transfected Glycoprotein Hormone α-Gene Expression in Primary Pituitary Cell Cultures,” Molecular Endocrinology 3(10):1643-1651, 1989.
Camerini-Otero, “Right on Target,” The New Biologist 2:337-341, 1990.
Cann et al., “High Efficiency Transfection of Primary Human Lymphocytes and Studies of Gene Expression,” Oncogene 3:123-128, 1988.
Capecchi, “High Efficiency Transformation By Direct Microinjection of DNA Into Cultured Mammalian Cells,” Cell 22:479-488, 1980.
Capecchi, “The New Mouse Genetics: Altering the Genome by Gene Targeting,” Trends in Genetics 5:70-76, 1989.
Capecchi,, “Altering the Genome by Homologous Recombination,” Science 244:1288-1292, 1989.
Chang et al., “High Efficiency Gene Transfection by Electroporation Using a Radio-Frequency Electric Field,” Biochimica et Biophysica Acta, 1092:153-160, 1991.
Chang et al., “Autologous Fibroblast Implantation Feasibility and Potential Problems in Gene Replacement Therapy,” Molecular Biology and Medicine, 7:461-470, 1990.
Cline, “Perspectives for Gene Therapy: Inserting New Genetic Information into Mammalian Cells by Physical Techniques and Viral Vectors,” Pharmacology and Therapy 29:69-92, 1985.
Corey et al., “Erythropoiesis in Murine Long-Term Marrow Cultures Following Transfer of the Erythropoietin cDNA into Marrow Stromal Cells,” Experimental Hematology, 18(3):201-204, 1990.
Crystal, “Transfer of Genes to Humans: Early Lessons and Obstacles to Success,” Science 270:404-410, 1995.
Daubas et al., “Functional Activity of the Two Promoters of the Myosin Alkali Light Chain Gene in Primary Muscle Cell Cultures: Comparison with Other Muscle Gene Promoters and Other Culture Systems,” Nucleic Acids Research 16(4):1251-1271, 1988.
Dhawan et al., “Systemic Delivery of Human Growth Hormone by Injection of Genetically Engineered Myoblasts,” Science 254:1509-1512, 1991.
Diatloff-Zito et al., “Abnormal Response to DNA Crosslinking Agents of Fanconi Anemia Fibroblasts can be Corrected by Transfection with Normal Human DNA,” Proceedings of the National Academy of Sciences U.S.A. 83:7034-7038, 1986.
Doering et al., “Expression of a Novel Gene Product by Transplants of Genetically Modified Primary Fibroblasts in the Central Nervous Systems,” Journal of Neuroscience Research 29:292-298, 1991.
Doetschman et al., “Targeted Correction of a Mutant HPRT Gene in Mouse Embryonic Stem Cells,” Nature, 330:576-578, 1987.
Doetschman et al., “Targeted Mutation of the HPRT Gene in Mouse Embryonic Stem Cells,” Proceedings of the National Academy of Sciences U.S.A. 85:8583-8587, 1988.
Drucker, et al., “Cell-Specific Post-Translational Processing of Preproglucagon Expressed from a Metallothionein-Glucagon Fusion Gene,” The Journal of Biological Chemistry 261(21):9637-9643, 1986.
Duncan et al., Biochemistry (Moscow) 62:1262-1274, 199
Heartlein Michael W.
Selden Richard F.
Treco Douglas
Clark & Elbing LLP
Katcheves Konstantina
Ketter James
Transkaryotic Therapies Inc.
LandOfFree
In Vivo production and delivery of erythropoietin or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with In Vivo production and delivery of erythropoietin or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and In Vivo production and delivery of erythropoietin or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3418332